NASDAQ:ATTO Attovia Therapeutics Q2 2026 Earnings Report $17.78 -0.39 (-2.15%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$17.80 +0.02 (+0.08%) As of 09/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Attovia Therapeutics EPS ResultsActual EPS-$4.88Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAttovia Therapeutics Revenue ResultsActual Revenue$0.45 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAttovia Therapeutics Announcement DetailsQuarterQ2 2026Date9/2/2026TimeAfter Market ClosesConference Call DateWednesday, September 2, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Attovia Therapeutics Earnings HeadlinesAttovia Therapeutics Inc (ATTO)September 25 at 2:39 PM | investing.comAttovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still FitsSeptember 22, 2026 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 26 at 1:00 AM | Porter & Company (Ad)Attovia Therapeutics (NASDAQ:ATTO) Raised to "Sell" at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comAttovia Therapeutics consensus price target increased by 344.21% to $43.04September 17, 2026 | msn.comAttovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSee More Attovia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Attovia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Attovia Therapeutics and other key companies, straight to your email. Email Address About Attovia TherapeuticsAttovia Therapeutics (NASDAQ:ATTO) (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease. The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs. Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on advancing its immunology and inflammation pipeline.View Attovia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
